Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Posted: February 13, 2025 at 2:44 am

Study Progresses to Fourth Higher 90 mg/m2 Dose Cohort

Link:
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Related Posts